Infographic: The Future of Prostate Cancer Biomarkers Is Multiplexed

Combining urinary biomarkers improves clinical utility and provides a more robust evaluation

Oreoluwa Ogunyemi, MD

Combining urinary biomarkers allows a complete evaluation of prostate cancer cells while minimizing the risk of missing a foci of cancer or a unique mutation that drives clinical outcomes.

Here, we explore commercially available multiplex urine biomarkers for detecting prostate cancer.

To learn about the future of prostate cancer biomarkers, download the FREE infographic courtesy of Clinical Lab Manager.